Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
52 studies found for:    PDGFRA
Show Display Options
Rank Status Study
1 Recruiting Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Condition: Recurrent/Refractory Glioblastoma
Intervention: Drug: crenolanib
2 Completed Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Other: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
3 Recruiting Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Condition: GIST With D842V Mutated PDGFRA Gene
Interventions: Drug: Crenolanib;   Drug: Placebo
4 Completed Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene
Condition: D842-related Mutant GIST
Intervention: Drug: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
5 Completed Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors
Conditions: Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing Approach;   Investigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients
6 Terminated
Has Results
A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Biological: Olaratumab
7 Completed
Has Results
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Condition: Adult Glioblastoma Multiforme
Interventions: Biological: olaratumab;   Biological: ramucirumab
8 Completed
Has Results
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Biological: Olaratumab;   Drug: liposomal doxorubicin
9 Completed A Study of IMC-3G3 in Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: IMC-3G3;   Drug: Mitoxantrone
10 Recruiting A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment
Conditions: Gastrointestinal Stromal Tumors;   Germline Mutation;   Somatic Mutation;   Plasma Concentration
11 Recruiting Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Condition: Malignant Neoplasm
Interventions: Drug: ponatinib hydrochloride;   Other: laboratory biomarker analysis
12 Completed
Has Results
A Study of Olaratumab in Soft Tissue Sarcoma
Condition: Sarcoma, Soft Tissue
Interventions: Biological: Olaratumab;   Drug: doxorubicin
13 Completed Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
Condition: Solid Tumors
Intervention: Biological: IMC-3G3
14 Active, not recruiting
Has Results
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Interventions: Biological: Olaratumab;   Drug: Paclitaxel;   Drug: Carboplatin
15 Completed Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
Condition: Platinum-resistant Advanced Ovarian Cancer
Intervention: Drug: Pazopanib
16 Terminated A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: imatinib mesylate
17 Completed
Has Results
A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
Condition: Cancer
Intervention: Drug: MEDI-575
18 Recruiting Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Condition: Advanced Cancer
Intervention: Drug: MGCD516
19 Unknown  Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia
Condition: Tumor Induced Oncogenic Osteomalacia
20 Completed Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: imatinib mesylate;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.